To the Editor: Nearly all of the patients in
the trial by Dr Lazarus and colleagues1
were previously receiving controller therapy with ICs. In addition to the
fact that one third of the trial participants were randomized to placebo for
16 weeks, all participants entered a 6-week "placebo runout" phase at the
conclusion of the trial in which controller therapy was withdrawn or withheld.